Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Xiangya Hospital of Central South University is the lead sponsor of 54 current clinical trials in our China register. 34 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Apatinib Mesylate, Morphine and Nivolumab. The most-studied condition is Parkinson Disease.

ClinicalTrials.gov trials by status

Recruiting3463%
Not yet open1019%
Active, closed713%
By invitation36%

Trials by phase

Observational3667%
Not applicable917%
Phase 447%
Phase 124%
Phase 1/212%
Phase 212%
Phase 312%

Clinical trials sponsored by Xiangya Hospital of Central South University

54 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Neuroprotection Bundles For Comatose Survivors Following Cardiac Arrest NCT06992843 · Cardiac Arrest, Post-cardiac Arrest Care	Not applicable	Recruiting	2025-10	China
Xiangya Cardiopulmonary Health and Disease Cohort NCT06972784 · ClinicalTrials.gov ↗ · Respiratory Function Tests，Heart Function Tests, Cardiopulmonary Function	Observational	Recruiting	2025-06	China
Observational Study About Patients Diagnosed With NAFLD NCT05625750 · ClinicalTrials.gov ↗ · Nonalcoholic Fatty Liver Disease	Observational	Recruiting	2022-04	China
Development and Application of Accurate Detection Technology Based on Multimodal Data of Breast Cancer Comobid Depression NCT06938373 · ClinicalTrials.gov ↗ · Breast Neoplasms	Observational	Recruiting	2025-03	China
Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery NCT07412223 · ClinicalTrials.gov ↗ · Pain, Postoperative, Postoperative Ileus Drugs: Morphine, Tegileridine	Phase 4	Recruiting	2026-02	China
Multicenter Cohort Study of AAV in Hunan of China NCT05315141 · ClinicalTrials.gov ↗ · ANCA Associated Vasculitis	Observational	Recruiting	2022-03	China
A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data NCT07126821 · ClinicalTrials.gov ↗ · Brain (Nervous System) Cancers, Brain Arterial Disease, Neuro-Degenerative Disease	Observational	Recruiting	2025-05	China
a Cohort Study of Ischemic Cerebrovascular Disease NCT05922540 · ClinicalTrials.gov ↗ · Ischaemic Stroke	Observational	Recruiting	2022-11	China
Chinese FPD Registry NCT03508986 · ClinicalTrials.gov ↗ · Parkinson Disease	Observational	Recruiting	2017-02	China
Chinese PD-LRRK2 Registry NCT03523104 · ClinicalTrials.gov ↗ · Parkinson Disease	Observational	Recruiting	2017-02	China
Multicenter Prospective Study on MRI AI Model for Midline Glioma Subtyping and Prognosis: NCT07608003 · ClinicalTrials.gov ↗ · Gliomas Harboring IDH1 and/or IDH2 Mutations, Glioma Glioblastoma Multiforme, Glioma of Brainstem	Observational	Recruiting	2026-05	China
Personalized Anticoagulant Therapy for Pulmonary Thromboembolism NCT06341231 · ClinicalTrials.gov ↗ · Pulmonary Thromboembolisms, Anticoagulants; Increased	Observational	Recruiting	2024-02	China
Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir NCT06399926 · ClinicalTrials.gov ↗ · Leptomeningeal Metastasis, Lung Cancer Drug: Pemetrexed	Observational	Recruiting	2023-10	China
Sleep Disordered Breathing and Multimorbidity: The Xiangya SDB Cohort Study NCT06755840 · ClinicalTrials.gov ↗ · Sleep Disordered Breathing (SDB), Sleep Apnea, Cardiometabolic Diseases	Observational	Recruiting	2025-01	China
Acupuncture for Refractory Rosacea: A Study on Its Effectiveness and Safety NCT07296497 · ClinicalTrials.gov ↗ · Rosacea	Not applicable	Recruiting	2025-12	China
Chinese DENOVO PD Registry NCT05767151 · ClinicalTrials.gov ↗ · Parkinson Disease	Observational	Recruiting	2021-01	China
Antiviral Therapy for Patients With Liver Cancer After Surgery NCT05466565 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Observational	Recruiting	2021-12	China
L-arginine for Knee Osteoarthritis Patients NCT06054633 · ClinicalTrials.gov ↗ · Osteoarthritis, Knee	Not applicable	Recruiting	2024-03	China
Chinese ET Registry (CETR) NCT04198246 · ClinicalTrials.gov ↗ · Essential Tremor	Observational	Recruiting	2019-01	China
Development and Validation of a Prognostic Model for Neurocritical Patients Using Multimodal Brain Monitoring NCT07115459 · ClinicalTrials.gov ↗ · Acute Brain Injury Coma, Neurocritical Care, Cerebral Infarction	Observational	Recruiting	2024-01	China
Establishment of Diagnosis and Classification System for Lung Interstitial and Airway Diseases (LIAD) NCT06987266 · ClinicalTrials.gov ↗ · Interstitial Lung Diseases (ILD), Airway Disease	Observational	Recruiting	2025-05	China
Comparison of Conservative and Endovascular Treatment for Spontaneously Isolated Superior Mesenteric Artery Dissection NCT05342233 · ClinicalTrials.gov ↗ · Spontaneous Isolated Superior Mesenteric Artery Dissection	Observational	Recruiting	2022-04	China
Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST NCT05751733 · ClinicalTrials.gov ↗ · Gastrointestinal Stromal Tumors Drug: Apatinib Mesylate	Not applicable	Recruiting	2023-02	China
Urinary Proteomic Assessment of Ovarian Malignancy and Disease Progression NCT06760923 · ClinicalTrials.gov ↗ · Ovarian Cancer (OvCa)	Observational	Recruiting	2025-01	China
Chinese PD Registry NCT03887663 · ClinicalTrials.gov ↗ · Parkinson Disease	Observational	Recruiting	2017-02	China
Study on the Treatment of Hepatitis B Virus(HBV) Infected Individuals With Peginterferon α-2b Combined With NA. NCT06746701 · ClinicalTrials.gov ↗ · HBV Drug: Peg-IFNα-2b	Observational	Recruiting	2023-05	China
The Impact of Anxiety/Depression on the Efficacy of Asthma Control Drugs and the Construction of a Predictive Model for the Risk of Acute Asthma Attacks NCT07679321 · ClinicalTrials.gov ↗ · Anxiety/Depression and Asthma	Observational	Recruiting	2024-12	China
Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Global Developmental Delay NCT07369960 · ClinicalTrials.gov ↗ · Developmental Delay Disorder, Repetitive Transcranial Magnetic Stimulation (rTMS), Global Developmental Delay	Not applicable	Recruiting	2026-05	China
Chinese PD-SNCA Registry NCT03523052 · ClinicalTrials.gov ↗ · Parkinson Disease	Observational	Recruiting	2017-02	China
Chinese PD-GBA Registry NCT03523065 · ClinicalTrials.gov ↗ · Parkinson Disease	Observational	Recruiting	2017-02	China
Treatment and Prognosis of Patients With Chronic HBV Infection NCT05392387 · ClinicalTrials.gov ↗ · Hepatitis B Virus Infection	Observational	Recruiting	2021-10	China
Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke NCT07369999 · ClinicalTrials.gov ↗ · Mild Disabling Acute Ischemic Stroke	Phase 3	Recruiting	2026-02	China
Chinese EOPD Registry NCT03508960 · ClinicalTrials.gov ↗ · Parkinson Disease	Observational	Recruiting	2017-02	China
TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma. NCT05872880 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma	Observational	Recruiting	2022-04	China
EEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes NCT07760415 · ClinicalTrials.gov ↗ · Sepsis, Sepsis Associated Encephalopathy, Sepsis and Septic Shock	Observational	Not yet open	2026-08	China
Impact of Radiotherapy-Immunotherapy Timing in NSCLC Brain Metastases NCT07638709 · ClinicalTrials.gov ↗ · Non Small Cell Lung, Brain Metastasases	Observational	Not yet open	2026-06	China
A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure NCT07783815 · ClinicalTrials.gov ↗ · Bladder Cancer Drug: Toripalimab	Phase 1	Not yet open	2026-09	China
Infrared Fluorescence Staining Versus Frozen Section for Prostate Cancer Surgery NCT07690462 · ClinicalTrials.gov ↗ · Prostate Cancer	Observational	Not yet open	2026-07	China
A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer NCT06866977 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drug: Oncolytic virus VRT106	Phase 1/2	Not yet open	2025-03	China
Paracetamol and Mannitol Injection and Postoperative Delirium NCT07235995 · ClinicalTrials.gov ↗ · Postoperative Delirium, Elderly, Non Cardiac Surgery	Phase 4	Not yet open	2025-12	China
Safety and Efficacy of Perioperative Volume Replacement with Volulyte 6% in Moderate-to-high Cardiovascular Risk Patients Having Major Abdominal Surgery NCT06663254 · ClinicalTrials.gov ↗ · Perioperative Volume Replacement, Hydroxyethyl Starch	Phase 4	Not yet open	2024-11	China
the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery NCT06530563 · ClinicalTrials.gov ↗ · Acute Pain, Opioid Analgesic Adverse Reaction Drugs: Oliceridine, Sufentanil Citrate	Phase 4	Not yet open	2025-08	China
Effect of Biologic vs Synthetic Mesh on Chronic Pain After Laparoscopic Repair of Contralateral Asymptomatic Hernia in Patients With Unilateral Symptomatic Inguinal Hernia NCT07649434 · ClinicalTrials.gov ↗ · Hernia Inguinal, Biologic Mesh	Not applicable	Not yet open	2026-06	China
Comparison of Liposomal Bupivacaine Paravertebral Nerve Block Versus Intercostal Nerve Block on Postoperative Glycemic Variability in Patients Undergoing Minimally Invasive Pulmonary Resection: A Randomized Controlled Non-Inferiority Trial NCT07754916 · ClinicalTrials.gov ↗ · Thoracic Surgery, Glycemic Variability	Not applicable	Not yet open	2026-08	China
JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study NCT06882876 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma (HCC)	Phase 1	By invitation	2025-07	China
Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT NCT07690306 · ClinicalTrials.gov ↗ · Prostate Cancer (Diagnosis)	Observational	By invitation	2026-01	China
AI-based Prediction of Prostate Cancer Metastasis Using Biopsy Pathology NCT07660276 · ClinicalTrials.gov ↗ · Prostate Cancer Metastatic	Observational	By invitation	2026-01	China
The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC NCT06243679 · ClinicalTrials.gov ↗ · Resectable/Potentially Resectable NSCLC	Observational	Active, closed	2020-07	China
The Advantages and Disadvantages of Linear Anastomat and Tubular Anastomat in Radical Gastrectomy of Distal Gastric Cancer NCT07080879 · ClinicalTrials.gov ↗ · Gastric Cancer	Not applicable	Active, closed	2023-06	China
Sofosbuvir/Velpatasvir/Voxilaprevir Salvage Therapy in Hepatitis C Patients Who Relapsed After DAA Treatment NCT07565948 · ClinicalTrials.gov ↗ · Hepatitis C Virus (HCV)	Observational	Active, closed	2022-01	China
Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC NCT04699721 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage ⅢA, Non-small Cell Lung Cancer Stage IIIB Drug: Nivolumab	Phase 2	Active, closed	2020-07	China
A Population-based Cohort of Osteoarthritis: the Xiangya Osteoarthritis Study NCT04033757 · ClinicalTrials.gov ↗ · Osteoarthritis	Observational	Active, closed	2015-11	China
Microfocused Ultrasound for Facial Pigmentary Diseases and Rosacea NCT07667972 · ClinicalTrials.gov ↗ · Melasma, Rosacea, Periorbital Hyperpigmentation	Not applicable	Active, closed	2025-10	China
An Organoid-on-chips Technique Based on Biopsy Samples and Its Efficacy in Predicting the Response to HAI in HCC NCT05932836 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma	Observational	Active, closed	2023-03	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Xiangya Hospital of Central South University trials

10 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Apatinib Mesylate1 Morphine1 Nivolumab1 Oliceridine1 Oncolytic virus VRT1061 Peg-IFNα-2b1 Pemetrexed1 Sufentanil Citrate1 Tegileridine1 Toripalimab1

Conditions in Xiangya Hospital of Central South University trials

83 conditions

Parkinson Disease7Rosacea2Hepatocellular Carcinoma2 Cardiac Arrest1Post-cardiac Arrest Care1Respiratory Function Tests，Heart Function Tests1Cardiopulmonary Function1Sepsis1Sepsis Associated Encephalopathy1Sepsis and Septic Shock1Sepsis at Intensive Care Unit1Nonalcoholic Fatty Liver Disease1Breast Neoplasms1Resectable/Potentially Resectable NSCLC1Gastric Cancer1Pain, Postoperative1Postoperative Ileus1ANCA Associated Vasculitis1Brain (Nervous System) Cancers1Brain Arterial Disease1Neuro-Degenerative Disease1Brain Tumors1Hepatocellular Carcinoma (HCC)1Ischaemic Stroke1

By trial register

Register	Trials	Recruiting
Clinical trials in China	54	34

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Parkinson Disease

Sponsor	Trials
Anhui Medical University	4
InSightec	2
iRegene Therapeutics	2
AskBio	1
BlueRock Therapeutics	1

Sponsors with the most current trials registered for this condition.

Questions about Xiangya Hospital of Central South University trials

How many clinical trials does Xiangya Hospital of Central South University sponsor?

Xiangya Hospital of Central South University is the lead sponsor of 54 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Xiangya Hospital of Central South University trials recruiting?

Yes. 34 of its 54 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Xiangya Hospital of Central South University testing?

Its current trials name 10 drugs and biologicals as interventions. The most frequent are Apatinib Mesylate (1), Morphine (1), Nivolumab (1), Oliceridine (1) and Oncolytic virus VRT106 (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Xiangya Hospital of Central South University clinical trials